| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/23/2009 | US20090105299 c-MET MODULATORS AND METHODS OF USE |
| 04/23/2009 | US20090105282 Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using pde 5 inhibitors |
| 04/23/2009 | US20090105281 Methods of treating inflammation |
| 04/23/2009 | US20090105270 Kinase inhibition and anticancer therapy |
| 04/23/2009 | US20090105264 Substituted Nicotinamide Compounds |
| 04/23/2009 | US20090105261 Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same |
| 04/23/2009 | US20090105254 Vhr protein tyrosine phosphatase inhibitors, compositions and methods of use |
| 04/23/2009 | US20090105251 Renin inhibitors |
| 04/23/2009 | US20090105247 tert-butyl 4-((4-(3-ethynylphenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate, used for treating or preventing physiological disorder caused by epidermal growth factor receptor (EGFR) or ERBB/Her-2 gene overexpression in mammals; anticarcinogenic agents |
| 04/23/2009 | US20090105240 Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same |
| 04/23/2009 | US20090105233 Serine-threonine protein kinase and parp modulators |
| 04/23/2009 | US20090105216 3- (aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors |
| 04/23/2009 | US20090105213 Lactam compounds useful as protein kinase inhibitors |
| 04/23/2009 | US20090105211 Inhibitors of hedgehog pathway |
| 04/23/2009 | US20090105206 Copper Melphalan And Copper Tegafur As Anti-Tumor Agents |
| 04/23/2009 | US20090105205 Methods of treating disease states using antiangiogenic agents |
| 04/23/2009 | US20090105204 Therapeutic Uses for Aminosterol Compounds |
| 04/23/2009 | US20090105203 Compounds for treating viral infections |
| 04/23/2009 | US20090105202 Androsterone Derivatives and Method of Use thereof |
| 04/23/2009 | US20090105200 Combination therapy |
| 04/23/2009 | US20090105192 Glycosaminoglycans derived from k5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation |
| 04/23/2009 | US20090105186 Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases |
| 04/23/2009 | US20090105179 Drug carriers |
| 04/23/2009 | US20090105166 Novel lapachone compounds and methods of use thereof |
| 04/23/2009 | US20090105156 Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| 04/23/2009 | US20090105153 Gonadotropin Releasing Hormone Antagonists |
| 04/23/2009 | US20090105145 Method of Diagnosing and Treating Colon Cancer |
| 04/23/2009 | US20090105135 Therapeutic Agent for Cancer |
| 04/23/2009 | US20090105133 Gamma-Delta T Cell Receptors |
| 04/23/2009 | US20090105130 Depsipeptide-containing injection solution |
| 04/23/2009 | US20090105128 Cannabinoid receptor targeted agent |
| 04/23/2009 | US20090105120 Method for preparing tryptophan rich peptides |
| 04/23/2009 | US20090105118 Preparation and applications of novel complexes made by gamma-polyglutamic acid and cisplatin |
| 04/23/2009 | US20090104697 Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells |
| 04/23/2009 | US20090104684 Diagnosis of carcinomas |
| 04/23/2009 | US20090104631 Psca: prostate stem cell antigen and uses thereof |
| 04/23/2009 | US20090104618 Diagnosing high grade ductal carcinoma (mammary glands) in situ (DCIS) by determining the level of psoriasin gene expression in a sample |
| 04/23/2009 | US20090104259 Compositions and methods for sirna inhibition of angiogenesis |
| 04/23/2009 | US20090104230 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/23/2009 | US20090104225 using recombinant modified vaccinia virus Ankara (MVA) encoding a polypeptide comprising a human prostate-specific antigen (PSA) antigen and another encoding prostatic acid phosphatase (PAP); can induce B- and T-cell responses |
| 04/23/2009 | US20090104223 Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations |
| 04/23/2009 | US20090104212 Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption |
| 04/23/2009 | US20090104201 Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
| 04/23/2009 | US20090104199 Breast Cancer Resistance Protein (BCRP) And The DNA Which Encodes It |
| 04/23/2009 | US20090104195 Targeted ligands |
| 04/23/2009 | US20090104192 Monoclonal Antibodies to Hepatocyte Growth Factor |
| 04/23/2009 | US20090104189 Neutrokine-alpha and neutrokine-alpha splice variant |
| 04/23/2009 | US20090104187 Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies |
| 04/23/2009 | US20090104186 Melanoma-associated MHC class I associated oligopeptides and the uses thereof |
| 04/23/2009 | US20090104180 Using selectin/immunoglobulin fusion for quelling organ transplant rejection |
| 04/23/2009 | US20090104179 Ionizing-radiation-responsive compositions, methods, and systems |
| 04/23/2009 | US20090104161 Method for activation treatment of antigen-presenting cell |
| 04/23/2009 | US20090104156 A recombinant virus into the genome of which is inserted DNA sequences coding for polypeptides of the early 6, the early E7, the late L1, the late L2 polypeptides of a papillomavirus ( HPV) and polypeptide having an immunostimulatory activity; antitumor/carcinogenic agents; gene therapy; uterus |
| 04/23/2009 | US20090104154 Composition and method for killing of tumours |
| 04/23/2009 | US20090104151 Smac mimetic dimers and trimers useful as anti-cancer agents |
| 04/23/2009 | US20090104150 Polymer conjugates of interferon Beta-1a and uses |
| 04/23/2009 | US20090104143 Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells |
| 04/23/2009 | US20090104120 Dlx1 cancer markers |
| 04/23/2009 | US20090104119 Dendrimer Based Compositions And Methods Of Using The Same |
| 04/23/2009 | US20090104116 Compounds for the inhibition of integrins and use thereof |
| 04/23/2009 | US20090104115 Cancerous disease modifying antibodies |
| 04/23/2009 | US20090104114 Nanotherapeutic Colloidal Metal Compositions and Methods |
| 04/23/2009 | DE102008009039A1 Neue Verbindungen aus Antrodia camphorata New compounds from Antrodia camphorata |
| 04/23/2009 | DE102007049451A1 5-Cyano-thienopyridine 5-cyano-thienopyridine |
| 04/23/2009 | CA2704201A1 Novel sulfated oligosaccharide derivatives |
| 04/23/2009 | CA2703720A1 Improved antitumoral treatments |
| 04/23/2009 | CA2703024A1 Improved antitumoral treatments |
| 04/23/2009 | CA2702950A1 Methods and compounds for modulating cannabinoid activity |
| 04/23/2009 | CA2702939A1 Anti-bst2 antibody |
| 04/23/2009 | CA2702930A1 Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| 04/23/2009 | CA2702922A1 Spiro-condensed 1,3,4-thiadiazole derivatives for inhibiting ksp kinesin activity |
| 04/23/2009 | CA2702898A1 Inhibitors of c-fms kinase |
| 04/23/2009 | CA2702838A1 Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
| 04/23/2009 | CA2702805A1 Clioquinol for the treatment of hematological malignancies |
| 04/23/2009 | CA2702699A1 Csf-1r inhibitors compositions, and mthods of use |
| 04/23/2009 | CA2702674A1 Heteroaryl compounds and uses thereof |
| 04/23/2009 | CA2702655A1 Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
| 04/23/2009 | CA2702644A1 A3 adenosine receptor antagonists |
| 04/23/2009 | CA2702551A1 5-cyanothienopyridines |
| 04/23/2009 | CA2702473A1 Antibodies that bind il-4 and/or il-13 and their uses |
| 04/23/2009 | CA2702315A1 Combination 059 |
| 04/23/2009 | CA2702300A1 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| 04/23/2009 | CA2702274A1 2'-flu0r0-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors |
| 04/23/2009 | CA2702039A1 Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo |
| 04/23/2009 | CA2701953A1 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
| 04/23/2009 | CA2700905A1 C7-substituted camptothecin analogs |
| 04/23/2009 | CA2700243A1 New no-donor aspirin derivatives |
| 04/23/2009 | CA2699356A1 Crystalline chemotherapeutic |
| 04/23/2009 | CA2699354A1 Crystalline chemotherapeutic |
| 04/23/2009 | CA2699353A1 Crystalline chemotherapeutic |
| 04/23/2009 | CA2699352A1 Crystalline indazole-derived chemotherepeutic |
| 04/23/2009 | CA2699302A1 Crystalline chemotherapeutic |
| 04/23/2009 | CA2699075A1 Use of a peptide as a therapeutic agent |
| 04/23/2009 | CA2690732A1 Rnai mediated knockdown of numa for cancer therapy |
| 04/22/2009 | EP2050762A2 Novel polypeptides and nucleic acids encoding the same |
| 04/22/2009 | EP2050750A2 Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes |
| 04/22/2009 | EP2050749A1 Pyrimidine derivative as pi3k inhibitor and use thereof |
| 04/22/2009 | EP2050748A1 Novel fused pyrimidines |
| 04/22/2009 | EP2050747A1 Dimers of harmol or of its derivatives and uses thereof |
| 04/22/2009 | EP2050744A1 Quinazoline derivatives as angiogenesis inhibitors |